Why Indivior’s Perseris once-monthly shot is drawing quiet attention

Reviewed: ad hoc news B2B & Pro desk. Edited and checked on 2026-06-20, 12:06. Details in the imprint.

With Perseris, Indivior puts a once-monthly risperidone injection into the hands of psychiatrists who want stability without daily pill reminders. The prefilled syringe vanishes in one quick subcutaneous shot, then quietly releases its payload over four weeks.

What Perseris is designed to do

Perseris is a long-acting injectable formulation of the antipsychotic risperidone, approved in the US for adults with schizophrenia and given as a once-monthly subcutaneous shot in the abdomen or back of the upper arm. Official Perseris HCP information The aim is simple but ambitious: steady symptom control with fewer gaps in treatment.

The drug uses a polymer-based delivery system that slowly releases risperidone over a full month after injection. FDA prescribing information For clinicians, that means one calendar date to remember instead of managing a daily swallowing routine that can crumble under stress, side effects, or lack of insight.

Dosing, handling, and the injection itself

Indivior markets Perseris in two strengths - 90 mg and 120 mg - supplied as a combination of a liquid and a powder that the healthcare professional mixes directly in a prefilled syringe before use. Dosing and administration guide There is no needle fiddling for the patient, only the quick sting of a subcutaneous shot.

Before starting Perseris, patients must first tolerate oral risperidone to confirm they do not react poorly to the compound. FDA prescribing information In the clinic, the preparation step adds a few minutes, but nurses report that the ready-to-use kit feels tidy compared with juggling vials, needles, and separate syringes.

How it fits into schizophrenia care

For psychiatrists, Perseris enters a crowded field of long-acting injectables that includes monthly and even three-monthly rivals based on risperidone or other antipsychotics. Its distinct angle is subcutaneous administration rather than deep intramuscular injections in the gluteal muscle.

That difference is not just academic. A subcutaneous shot in the abdomen or upper arm can feel less invasive and more discreet for many patients who dread the ritual of pulling down clothing for a depot injection. It also gives clinics flexibility when arranging nurse-led injection visits.

Benefits patients may actually feel

When Perseris works as intended, the effect is not flashy. Patients and families describe something quieter - fewer abrupt mood swings, less paranoia spiking after missed pills, and a more predictable baseline across the month.

For some, the psychological relief of not staring at a blister strip every morning is almost as important as the pharmacology. Treatment becomes one appointment circled on the calendar rather than a daily test of willpower or memory.

Where Perseris has limits and side effects

Like other risperidone-based treatments, Perseris carries the familiar baggage of possible weight gain, prolactin elevation, and movement-related side effects such as restlessness or tremor. FDA prescribing information Once the shot is given, side effects can linger because the drug continues to release over weeks.

Clinicians also need to pick patients carefully. Perseris is not indicated for acute agitation or for children, and it is not a fit for every adult with schizophrenia, especially those needing very fine dose adjustments or those with a history of strong sensitivity to risperidone.

Pricing, coverage, and who actually uses it

Perseris is marketed primarily in the US, where Indivior targets psychiatrists in community mental-health centers, outpatient clinics, and correctional or forensic settings. In many cases, uptake hinges on whether Medicaid or commercial insurers cover the monthly injection at reasonable co-pay levels for the patient.

In Europe, Perseris is not as visible as Indivior’s addiction-treatment portfolio, and availability can differ from country to country, so this remains largely a home-market story for now. For hospital pharmacy managers, the pitch is continuity of care after discharge, when oral adherence often crumbles.

How Perseris sits in Indivior’s portfolio and stock

Within Indivior’s line-up, Perseris complements the better-known opioid-dependence therapies and expands the company’s footprint in chronic psychiatric conditions. That diversification matters in a business that has long been heavily tied to one therapeutic area.

Shares of Indivior PLC (GB00BYZ0C031) trade in the US on Nasdaq under the symbol INDV, giving international investors straightforward access to the company’s mix of addiction and mental-health products.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.